Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients (DCCIK)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To access the effectiveness of cyclophosphamide combined thiotepa and carboplatin chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells in triple negative metastatic breast cancer patients
Condition or disease
Breast NeoplasmsNeoplasm Metastasis
Metastatic breast cancer patients should be definitively diagnosis based on histopathology, with ER-negative and PR-negative, FISH testing for her-2-negative
All the patients enrolled will be given standard cyclophosphamide combined thiotepa and carboplatin chemotherapy and cellular therapy.Cellular therapy consisting of one cycle of chemotherapy followed by an apheresis and ex vivo cultures to generate DC and CIK, followed by low-dose Oral Cyclophosphamide .
The response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines.
Estimate time to progression, survival rates and clinical benefit response on patients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
female patients with metastatic breast cancer
Failure to anthracycline and/or taxol chemotherapy;
metastatic tumor is histologically confirmed by immunohistochemical staining to be ER-negative and PR-negative. FISH testing for her-2-negative;
Metastatic tumor can not be removed through surgery procedure;
An Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
Normal cardiac, hepatic, renal and bone marrow functions;
Life expectancy ≥3 months.
Central nervous system metastases;
Serious or uncontrolled concurrent medical illness;
History of other malignancies;
Having been enrolled in some other clinal trials within a month;